ArticleInternational journal of clinical and experimental pathology2025
Lactobacillus-based probiotic cocktail inhibits colitis-associated cancer by altering intestinal metabolism.
Article in International journal of clinical and experimental pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut microbial metabolites in inflammation-associated colorectal cancer: mechanisms and therapeutic implications.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDysbiosis of intestinal microbiome is an important colorectal cancer (CRC) pathogenetic mechanism. Lactobacillus-based probiotic cocktail could inhibit colitis-associated cancer (CAC) by alleviating intestinal dysbiosis. The intestinal microbial metabolites have been linked with CRC etiology. However, the link between Lactobacillus-based probiotic cocktail and the alteration of intestinal metabolism and their functional mechanisms during CAC process is still poorly understood.
methodsFor assessing protective effects of the probiotic cocktail, azomethanes/dextran sodium sulfate (AOM/DSS) induced CAC mice were pretreated with the probiotic cocktail. Colon of C57BL/6 mice were used to assess inflammation and tumorigenesis. Comparative analysis was performed for determining how the probiotic altered intestinal metabolism and gene expression. Meanwhile, intestinal microbiota alterations were analyzed. The concluding integrated analysis of intestinal metabolism and gene expression as well as intestinal microbiota was presented.
resultsPretreatment with the probiotic alleviated intestinal inflammation and limited the formation of tumors. Oncogenes were down-regulated and cancer suppressor genes were up-regulated after probiotic pretreatment. Pretreatment with the probiotic induced a rise of Lactobacillus-dominated genera and a reduction of potential pathogenic bacteria Parasutterella, Helicobacter and Muribaculum, and affected expression of intestinal metabolites that involved 37 metabolic pathways. Lactobacillus-associated intestinal metabolite variations involve five metabolic pathways - arginine and proline metabolism, histidine metabolism, pyrimidine metabolism, purine metabolism, and tyrosine metabolism.
conclusionsPretreatment with Lactobacillus-based probiotic cocktail protected mice from CAC by interfering with intestinal metabolites that affected the cancer suppressor genes and oncogenes' expression. Furthermore, Lactobacillus affected five metabolite pathways, which was important mechanism for probiotic anti-inflammatory and anti-tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.